MERS-CoV vaccine
Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
1. A method of inducing an immune response against a Middle East Respiratory Syndrome coronavirus (MERS-CoV) in a subject in need thereof, the method comprising administering to the subject an immunogenic composition comprising a peptide comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:2; and
b) an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:4.
2. The method of claim 1 , wherein administering includes at least one of electroporation and injection.
3. A method of protecting a subject in need thereof from infection with a Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering to the subject an immunogenic composition comprising a peptide comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:2; and
b) an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:4.
4. The method of the claim 3 , wherein administering includes at least one of electroporation and injection.
5. A method of treating a subject in need thereof against Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering to the subject, an immunogenic composition comprising a peptide comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:2; and
b) an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:4;
wherein the subject is thereby resistant to one or more MERS-CoV strains.
6. The method of claim 5 , wherein administering includes at least one of electroporation and injection.